GuidePrimary care
Prostate cancer screening with PSA (CTFPHC 2014)
Canadian recommendation on prostate cancer screening with PSA in men without a previous diagnosis.
Updated 3 November 2026
When to use it
When a man without known prostate cancer asks about PSA or PSA screening is being considered.
Warning
The CTFPHC ended its mandate on 31 March 2026: its guidelines remain published but are no longer updated (the Public Health Agency of Canada now supports a national advisory committee). They are Canadian recommendations: check them against your national or regional screening programme.
Who it applies to
All men not previously diagnosed with prostate cancer, including those with lower urinary tract symptoms (nocturia, urgency, frequency, weak stream) or benign prostatic hyperplasia.
Keep reading in the app
- Recommendations
- Benefits and harms
- How to apply it
Practical tip
It recommends against PSA screening at any age; in men aged 55–69 the recommendation is weak and allows shared decision-making.
2 more practical tips in the app.
Reference
- Bell N, et al.; Canadian Task Force on Preventive Health Care. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ. 2014;186(16):1225-1234.
- US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913.
Official source: CTFPHC guideline (Canadian Task Force on Preventive Health Care)
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
